GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Skystar Bio-Pharmaceutical Co (GREY:SKBI) » Definitions » Asset Turnover

Skystar Bio-Pharmaceutical Co (Skystar Bio-Pharmaceutical Co) Asset Turnover : 0.11 (As of Sep. 2014)


View and export this data going back to . Start your Free Trial

What is Skystar Bio-Pharmaceutical Co Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Skystar Bio-Pharmaceutical Co's Revenue for the three months ended in Sep. 2014 was $18.35 Mil. Skystar Bio-Pharmaceutical Co's Total Assets for the quarter that ended in Sep. 2014 was $164.09 Mil. Therefore, Skystar Bio-Pharmaceutical Co's Asset Turnover for the quarter that ended in Sep. 2014 was 0.11.

Asset Turnover is linked to ROE % through Du Pont Formula. Skystar Bio-Pharmaceutical Co's annualized ROE % for the quarter that ended in Sep. 2014 was 16.64%. It is also linked to ROA % through Du Pont Formula. Skystar Bio-Pharmaceutical Co's annualized ROA % for the quarter that ended in Sep. 2014 was 11.97%.


Skystar Bio-Pharmaceutical Co Asset Turnover Historical Data

The historical data trend for Skystar Bio-Pharmaceutical Co's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Skystar Bio-Pharmaceutical Co Asset Turnover Chart

Skystar Bio-Pharmaceutical Co Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.73 0.67 0.57 0.31 0.34

Skystar Bio-Pharmaceutical Co Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.07 0.05 0.10 0.11

Competitive Comparison of Skystar Bio-Pharmaceutical Co's Asset Turnover

For the Drug Manufacturers - General subindustry, Skystar Bio-Pharmaceutical Co's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Skystar Bio-Pharmaceutical Co's Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Skystar Bio-Pharmaceutical Co's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Skystar Bio-Pharmaceutical Co's Asset Turnover falls into.



Skystar Bio-Pharmaceutical Co Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Skystar Bio-Pharmaceutical Co's Asset Turnover for the fiscal year that ended in Dec. 2013 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2013 )/( (Total Assets (A: Dec. 2012 )+Total Assets (A: Dec. 2013 ))/ count )
=42.484/( (115.759+136.223)/ 2 )
=42.484/125.991
=0.34

Skystar Bio-Pharmaceutical Co's Asset Turnover for the quarter that ended in Sep. 2014 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2014 )/( (Total Assets (Q: Jun. 2014 )+Total Assets (Q: Sep. 2014 ))/ count )
=18.353/( (156.565+171.608)/ 2 )
=18.353/164.0865
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Skystar Bio-Pharmaceutical Co  (GREY:SKBI) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Skystar Bio-Pharmaceutical Co's annulized ROE % for the quarter that ended in Sep. 2014 is

ROE %**(Q: Sep. 2014 )
=Net Income/Total Stockholders Equity
=19.636/118.0035
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(19.636 / 73.412)*(73.412 / 164.0865)*(164.0865/ 118.0035)
=Net Margin %*Asset Turnover*Equity Multiplier
=26.75 %*0.4474*1.3905
=ROA %*Equity Multiplier
=11.97 %*1.3905
=16.64 %

Note: The Net Income data used here is four times the quarterly (Sep. 2014) net income data. The Revenue data used here is four times the quarterly (Sep. 2014) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Skystar Bio-Pharmaceutical Co's annulized ROA % for the quarter that ended in Sep. 2014 is

ROA %(Q: Sep. 2014 )
=Net Income/Total Assets
=19.636/164.0865
=(Net Income / Revenue)*(Revenue / Total Assets)
=(19.636 / 73.412)*(73.412 / 164.0865)
=Net Margin %*Asset Turnover
=26.75 %*0.4474
=11.97 %

Note: The Net Income data used here is four times the quarterly (Sep. 2014) net income data. The Revenue data used here is four times the quarterly (Sep. 2014) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Skystar Bio-Pharmaceutical Co Asset Turnover Related Terms

Thank you for viewing the detailed overview of Skystar Bio-Pharmaceutical Co's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Skystar Bio-Pharmaceutical Co (Skystar Bio-Pharmaceutical Co) Business Description

Traded in Other Exchanges
N/A
Address
No. 48 Keji Road, 4/F Building B, Chuangye Square, Gaoxin District, Xian, Shaanxi Province, CHN
Skystar Bio-Pharmaceutical Co is a holding company. Through its subsidiaries, it is engaged in the research, development, production, marketing, and sales of veterinary healthcare and medical care products in the People's Republic of China. The company provides individually packaged animal wellness and pharmaceutical products for retail sale. It generates revenue from the sales of four product lines namely, veterinary medications, micro-organism, feed additives, and vaccines. The firm develops, manufactures, packages and distributes vaccines; Western medicines, Traditional Chinese Medicine; topicals, supplements, probiotics; diagnostic kits and animal nutrition supplements for poultry, livestock, marine aquaculture and domesticated pets.

Skystar Bio-Pharmaceutical Co (Skystar Bio-Pharmaceutical Co) Headlines

No Headlines